150 related articles for article (PubMed ID: 18381104)
41. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
Blood; 2011 Aug; 118(8):2085-93. PubMed ID: 21670470
[TBL] [Abstract][Full Text] [Related]
42. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253
[TBL] [Abstract][Full Text] [Related]
43. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
Lin TS; Stock W; Xu H; Phelps MA; Lucas MS; Guster SK; Briggs BR; Cheney C; Porcu P; Flinn IW; Grever MR; Dalton JT; Byrd JC
Leuk Lymphoma; 2009 Dec; 50(12):1958-63. PubMed ID: 19860603
[TBL] [Abstract][Full Text] [Related]
44. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).
Schweighofer CD; Ritgen M; Eichhorst BF; Busch R; Abenhardt W; Kneba M; Hallek M; Wendtner CM
Br J Haematol; 2009 Jan; 144(1):95-8. PubMed ID: 19016732
[TBL] [Abstract][Full Text] [Related]
45. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia.
Byrd JC; O'Brien S; Flinn IW; Kipps TJ; Weiss M; Rai K; Lin TS; Woodworth J; Wynne D; Reid J; Molina A; Leigh B; Harris S
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4448-55. PubMed ID: 17671129
[TBL] [Abstract][Full Text] [Related]
46. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
Shanafelt TD; Lin T; Geyer SM; Zent CS; Leung N; Kabat B; Bowen D; Grever MR; Byrd JC; Kay NE
Cancer; 2007 Jun; 109(11):2291-8. PubMed ID: 17514743
[TBL] [Abstract][Full Text] [Related]
47. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
Kay NE; Geyer SM; Call TG; Shanafelt TD; Zent CS; Jelinek DF; Tschumper R; Bone ND; Dewald GW; Lin TS; Heerema NA; Smith L; Grever MR; Byrd JC
Blood; 2007 Jan; 109(2):405-11. PubMed ID: 17008537
[TBL] [Abstract][Full Text] [Related]
48. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
49. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Elter T; Borchmann P; Schulz H; Reiser M; Trelle S; Schnell R; Jensen M; Staib P; Schinköthe T; Stützer H; Rech J; Gramatzki M; Aulitzky W; Hasan I; Josting A; Hallek M; Engert A
J Clin Oncol; 2005 Oct; 23(28):7024-31. PubMed ID: 16145065
[TBL] [Abstract][Full Text] [Related]
50. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
[TBL] [Abstract][Full Text] [Related]
51. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Wierda W; O'Brien S; Wen S; Faderl S; Garcia-Manero G; Thomas D; Do KA; Cortes J; Koller C; Beran M; Ferrajoli A; Giles F; Lerner S; Albitar M; Kantarjian H; Keating M
J Clin Oncol; 2005 Jun; 23(18):4070-8. PubMed ID: 15767647
[TBL] [Abstract][Full Text] [Related]
52. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
[TBL] [Abstract][Full Text] [Related]
53. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
Byrd JC; Rai K; Peterson BL; Appelbaum FR; Morrison VA; Kolitz JE; Shepherd L; Hines JD; Schiffer CA; Larson RA
Blood; 2005 Jan; 105(1):49-53. PubMed ID: 15138165
[TBL] [Abstract][Full Text] [Related]
54. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
Wendtner CM; Ritgen M; Schweighofer CD; Fingerle-Rowson G; Campe H; Jäger G; Eichhorst B; Busch R; Diem H; Engert A; Stilgenbauer S; Döhner H; Kneba M; Emmerich B; Hallek M;
Leukemia; 2004 Jun; 18(6):1093-101. PubMed ID: 15071604
[TBL] [Abstract][Full Text] [Related]
55. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
Lozanski G; Heerema NA; Flinn IW; Smith L; Harbison J; Webb J; Moran M; Lucas M; Lin T; Hackbarth ML; Proffitt JH; Lucas D; Grever MR; Byrd JC
Blood; 2004 May; 103(9):3278-81. PubMed ID: 14726385
[TBL] [Abstract][Full Text] [Related]
56. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Thomas DA; Cortes J; Giles FJ; Wierda WG; Koller CA; Ferrajoli A; Browning M; Lerner S; Albitar M; Keating MJ
Cancer; 2003 Dec; 98(12):2657-63. PubMed ID: 14669286
[TBL] [Abstract][Full Text] [Related]
57. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Ely S; Furman RR; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Cesano A; Goldenberg DM
J Clin Oncol; 2003 Aug; 21(16):3051-9. PubMed ID: 12837807
[TBL] [Abstract][Full Text] [Related]
58. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
[TBL] [Abstract][Full Text] [Related]
59. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.
Byrd JC; Smith L; Hackbarth ML; Flinn IW; Young D; Proffitt JH; Heerema NA
Cancer Res; 2003 Jan; 63(1):36-8. PubMed ID: 12517774
[TBL] [Abstract][Full Text] [Related]
60. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study.
Itälä M; Geisler CH; Kimby E; Juvonen E; Tjonnfjord G; Karlsson K; Remes K
Eur J Haematol; 2002 Sep; 69(3):129-34. PubMed ID: 12406005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]